نتایج جستجو برای: tenofovir disproxil fumarate
تعداد نتایج: 10210 فیلتر نتایج به سال:
Background. Many human immunodeficiency virus (HIV)-infected patients remain on nevirapine-based antiretroviral therapy (ART) despite safety and efficacy concerns. Switching to a rilpivirine-based regimen is an alternative, but there is little experience with rilpivirine in sub-Saharan Africa where induction of rilpivirine metabolism by nevirapine, HIV subtype, and dietary differences could po...
OBJECTIVES In the context of simplification strategies, it is essential to know the feasibility of a switch to a rilpivirine-based therapy. The aim of this study was to describe rilpivirine, tenofovir and emtricitabine resistance in HIV-1-infected patients who experienced virological failure during their previous antiretroviral treatment. PATIENTS AND METHODS The studied population included t...
OBJECTIVE Bone mineral density (BMD) loss, a risk factor for osteoporosis, has been attributed to HIV infection and antiretroviral therapy (ART), including regimens containing tenofovir disoproxil fumarate. DESIGN Study 202094 is an open-label, parallel-group, sub-study of the phase III SWORD-1 and SWORD-2 studies (ClinicalTrials.gov identifier, NCT02478632). METHODS HIV-1-infected adults w...
PURPOSE OF REVIEW Current WHO-recommended first-line therapy in low-income and middle-income countries has been very successful in saving millions of lives but still has toxicity concerns and a low barrier to resistance. RECENT FINDINGS Two candidate antiretrovirals may substantially transform first-line therapy in low-income and middle-income countries, yielding a safer, more robust and chea...
In July 2006 Atriplatrade mark was approved by the US Food and Drug Administration (FDA), combining the active ingredients of one NNRTI and two NRTIs. Atriplatrade mark is the first "one-pill-daily" regimen licensed for the treatment of HIV-1 infection in patients older than 18 years. H was licensed in Europe in December 2007 Atriplatrade mark contains efavirenz 600 mg, emtricitabine 200 mg, an...
OBJECTIVE Atazanavir (ATV) and lopinavir (LPV) have been associated with kidney disease progression in HIV positive patients, with no data reported for darunavir (DRV). We examined kidney function in patients who switched their protease inhibitor from ATV or LPV to DRV. DESIGN Cohort study. METHODS Data were from the UK CHIC study. We compared pre and post switch estimated glomerular filtra...
BACKGROUND Approximately one-third of all HIV-infected individuals are coinfected with HCV, many of whom will receive concomitant treatment for both infections. With the advent of direct-acting antivirals (DAAs) for HCV, potential drug interactions between antiretrovirals and DAAs require evaluation prior to co-therapy. METHODS Three open-label studies were conducted in healthy subjects to as...
Abstract Background An easy, defined, rapid, and accurate reverse phase high-performance liquid chromatography method was developed subsequently validated for the concurrent estimation of lamivudine, efavirenz, tenofovir disoproxil fumarate in their pure blend combined tablet formulation. efficient appropriate separation three analytes attained with Zorbax eclipse XDB-Phenyl column, a mobile me...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید